Invesco
CRNX

Invesco’s Crinetics Pharmaceuticals CRNX Stock Holding History

Invesco’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.36M Sell
116,460
-17,006
-13% -$632K ﹤0.01% 2272
2026
Q1 		$4.85M Sell
133,466
-24,623
-16% -$1.1M ﹤0.01% 2208
2025
Q4 		$7.36M Buy
158,089
+68,696
+77% +$3.06M ﹤0.01% 2041
2025
Q3 		$3.72M Buy
89,393
+11,253
+14% +$360K ﹤0.01% 2358
2025
Q2 		$2.25M Buy
78,140
+8,181
+12% +$253K ﹤0.01% 2531
2025
Q1 		$2.35M Sell
69,959
-228,295
-77% -$8.53M ﹤0.01% 2482
2024
Q4 		$15.2M Buy
298,254
+42,954
+17% +$2.4M ﹤0.01% 1624
2024
Q3 		$13M Buy
255,300
+73,701
+41% +$3.8M ﹤0.01% 1703
2024
Q2 		$8.13M Buy
181,599
+4,656
+3% +$215K ﹤0.01% 1923
2024
Q1 		$8.28M Buy
176,943
+5,106
+3% +$200K ﹤0.01% 1924
2023
Q4 		$6.11M Sell
171,837
-5,536
-3% -$170K ﹤0.01% 2133
2023
Q3 		$5.28M Buy
177,373
+139,796
+372% +$2.88M ﹤0.01% 2179
2023
Q2 		$677K Sell
37,577
-833
-2% -$16.6K ﹤0.01% 3091
2023
Q1 		$617K Buy
38,410
+20,129
+110% +$373K ﹤0.01% 3149
2022
Q4 		$335K Sell
18,281
-366
-2% -$6.45K ﹤0.01% 3462
2022
Q3 		$366K Sell
18,647
-2,272
-11% -$46.3K ﹤0.01% 3416
2022
Q2 		$390K Buy
20,919
+1,576
+8% +$31.5K ﹤0.01% 3456
2022
Q1 		$425K Sell
19,343
-170,892
-90% -$3.46M ﹤0.01% 3475
2021
Q4 		$5.4M Buy
190,235
+173,734
+1,053% +$4.28M ﹤0.01% 2360
2021
Q3 		$347K Buy
16,501
+2,799
+20% +$58.6K ﹤0.01% 3591
2021
Q2 		$258K Buy
+13,702
New +$241K ﹤0.01% 3690

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's CRNX Position: Q2 2026 in Review

Invesco reduced its Crinetics Pharmaceuticals (CRNX) stake by 13% in Q2 2026, selling an estimated $632K and leaving 116,460 shares worth $4.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2272.

Invesco first reported a position in CRNX in Q2 2021 and has held it in 21 quarters since. The position peaked at $15.2M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • Invesco held 116,460 shares of Crinetics Pharmaceuticals worth $4.36M as of Q2 2026.
  • Invesco sold 17,006 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $632K.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2272 holding.
  • Invesco first reported a position in Crinetics Pharmaceuticals in Q2 2021 and has held it in 21 quarters since.
  • Invesco's Crinetics Pharmaceuticals position peaked at $15.2M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.